Undisclosed monoclonal antibody / Shilpa Medicare, mAbTree Biologics - LARVOL DELTA

Shilpa Biologicals and mAbTree Biologics received USFDA Orphan Drug Designation for a monoclonal antibody targeting Essential Thrombocythemia and Polycythemia Vera, advancing clinical trials. (CNBC-TV18) - "Following the regulatory milestone, the companies plan to advance the biologic through IND-enabling studies, with the aim of initiating first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera."

First-in-human • Orphan drug • Essential Thrombocythemia • Polycythemia Vera